Pazinib 200mg Tablet

About

Pazopanib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that blocks the activity of several key enzymes involved in cancer cell growth and blood vessel formation (angiogenesis). Specifically, it targets vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet-derived growth factor receptor (PDGFR)-α and -β, and c-Kit. By inhibiting these pathways, pazopanib helps to slow or stop the proliferation of cancer cells and reduce the blood supply to tumors, thereby impeding tumor growth and metastasis. It is primarily used in the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.

The mechanism of action involves binding to the intracellular domain of these receptors, preventing their phosphorylation and subsequent activation of downstream signaling pathways crucial for cell division, survival, and angiogenesis. This targeted approach offers a therapeutic advantage by specifically interfering with processes vital for cancer progression while minimizing damage to healthy cells, though systemic side effects can still occur due to the widespread nature of some targeted pathways. Regular monitoring is essential to manage potential adverse reactions and ensure optimal therapeutic outcomes.

Uses

• Advanced Renal Cell Carcinoma (RCC)
• Advanced Soft Tissue Sarcoma (STS)
• Certain types of metastatic cancer
• Inhibition of tumor angiogenesis

Directions For Use

Take this medication orally, usually once daily, on an empty stomach at least one hour before or two hours after a meal. Swallow the tablet whole with water; do not crush, chew, or break it.

Benefits

• Slows progression of advanced cancers.
• Inhibits tumor growth and metastasis.
• Reduces blood supply to tumors.
• Improves progression-free survival in specific cancers.
• Offers a targeted therapy approach.
• Available in convenient oral tablet form.

Side Effects

• Diarrhea
• Nausea and vomiting
• Fatigue
• Hypertension (high blood pressure)
• Hair color changes (depigmentation)
• Elevated liver enzymes
• Anorexia (loss of appetite)
• Headache
• Proteinuria (protein in urine)
• Hand-foot syndrome
• Thrombocytopenia (low platelet count)
• Hypothyroidism

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver side effects and interact with the medication.
• Pregnancy - Not recommended during pregnancy due to potential fetal harm; effective contraception is required for women of childbearing potential.
• Breastfeeding - Breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with pre-existing liver impairment; dose adjustments may be necessary, and liver function should be closely monitored.
• Kidney - Use with caution in patients with severe renal impairment; dose adjustments may be considered, and kidney function should be monitored.
• Lung - Monitor for signs of interstitial lung disease or pneumonitis; discontinue if suspected and manage appropriately.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.